CSIMarket

Johnson and Johnson  (JNJ)
Other Ticker:  
 
 
Price: $176.9800 $3.04 1.748%
Day's High: $177.16 Week Perf: -0.62 %
Day's Low: $ 174.05 30 Day Perf: -3.48 %
Volume (M): 7,522 52 Wk High: $ 186.69
Volume (M$): $ 1,331,261 52 Wk Avg: $169.44
Open: $174.85 52 Wk Low: $155.72



 Market Capitalization (Millions $) 471,917
 Shares Outstanding (Millions) 2,667
 Employees 132,200
 Revenues (TTM) (Millions $) 94,880
 Net Income (TTM) (Millions $) 19,830
 Cash Flow (TTM) (Millions $) -2,208
 Capital Exp. (TTM) (Millions $) 3,582

Johnson And Johnson
Johnson & Johnson, employing approximately 110,600 people worldwide, is engaged in the manufacture and sale of a broad range of products in the health care field. Through over 200 operating companies, it conducts business in virtually all countries of the world. Johnson & Johnson's primary interest, both historically and currently, has been in products related to human health and well-being. Johnson & Johnson was organized in the State of New Jersey in 1887.


Johnson & Johnson is organized on the principle of decentralized management. The Executive Committee of Johnson & Johnson is the principal management group responsible for the operations and allocation of the resources of the Company. This Committee oversees and coordinates the activities of the Consumer, Pharmaceutical and Medical Devices and Diagnostics business segments. Each subsidiary within the business segments is, with some exceptions, managed by citizens of the country in which it is located.


Johnson & Johnson's worldwide business is divided into three segments:

Consumer, Pharmaceutical and Medical Devices and Diagnostics.

CONSUMER

The Consumer segment manufactures and markets a broad range of products used in the baby and child care, skin care, oral and wound care and women's health care fields, as well as nutritional and over-the-counter pharmaceutical products.

PHARMACEUTICAL

The Pharmaceutical segment's principal worldwide franchises are in the antifungal, anti-infective, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, psychotropic (central nervous system) and urology fields.

MEDICAL DEVICES AND DIAGNOSTICS

The Medical Devices and Diagnostics segment includes a broad range of products used by or under the direction of physicians, nurses, therapists, hospitals, diagnostic laboratories and clinics.

The international business of Johnson & Johnson is conducted by subsidiaries located in 56 countries outside the United States, which are selling products in virtually all countries throughout the world.

COMPETITION

In all their product lines, Johnson & Johnson companies compete with companies both large and small, located in the United States and abroad. Competition is strong in all lines without regard to the number and size of the competing companies involved. Competition in research, involving the development of new products and processes and the improvement of existing products and processes, is particularly significant and results from time to time in product and process obsolescence. The development of new and improved products is important to Johnson & Johnson's success in all areas of its business.



   Company Address: One Johnson & Johnson Plaza New Brunswick 8933 NJ
   Company Phone Number: 524-0400   Stock Exchange / Ticker: NYSE JNJ
   JNJ is expected to report next financial results on July 28, 2022.


Customers Net Income grew by JNJ's Customers Net Profit Margin fell to

1.69 %

4.56 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

Year to Date Decrease / Increase
     
ABT   -18.56%    
BMY        23.13% 
LLY        9.98% 
MRK        21.7% 
PFE   -7.38%    
ABBV        11.51% 
CAH        7.29% 
DHR   -20.26%    
MCK        30.13% 
PG   -12.96%    
• View Complete Report
   



Finnovate Acquisition Corp.

Finnovate Acquisition Corp announced fiscal span ending Mar 31 2022 operating shortfall of $-0.17509 millions

In the fiscal span ending Mar 31 2022 Finnovate Acquisition Corp of $-0.01 per share compared to $ a year ago and from $0.00 per share from the previous quarter.

Gan Limited

Gan Limited announced Remarkable Achievement in the fiscal first quarter of 2022

In the fiscal first quarter of 2022 Gan Limited decreased loss of $-0.11 per share compared to $-0.13 a year ago and improved from $-0.30 per share from the previous quarter.

Bunker Hill Mining Corp.

Losses Widen but Revenues Unchanged

In the financial first quarter of 2022 Bunker Hill Mining Corp increased losses of $-0.02 per share compared to $0.00 a year ago and eps fell from $0.02 per share from the previous quarter.

Edge Data Solutions Inc.

EPS Fell while Sales More than Doubled

Despite very strong Sales growth of 46838.84% year on year to $6.59 millions in the first quarter of 2022, company faced turn a round at $0.07.

Pavmed Inc.

Pavmed Inc reported top-line remained unaltered in the first quarter of 2022

In the first quarter of 2022 Pavmed Inc loss increased of $-0.20 per share compared to $-0.13 a year ago and improved from $-0.24 per share from the previous quarter.






 

Johnson And Johnson's Segments
 
PROCRIT
 Segment    3.06 % of total Revenue
RISPERDAL
 Segment    2.82 % of total Revenue
REMICADE
 Segment    18.37 % of total Revenue
VELCADE
 Segment    3.84 % of total Revenue
CONCERTA
 Segment    2.42 % of total Revenue
INVEGA
 Segment    1.8 % of total Revenue
Other
 Segment    9.08 % of total Revenue
Total Pharmaceutical
 Segment    44.67 % of total Revenue
Med. Dev. & Diag.
 Segment    35.75 % of total Revenue
Nutritionals
 Segment    5.48 % of total Revenue
Skin Care
 Segment    5.03 % of total Revenue
Total Consumer
 Segment    19.58 % of total Revenue
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Johnson And Johnson does not provide revenue guidance.

Earnings Outlook
Pavmed Inc. does not provide earnings estimates.

 
Geographic Revenue Dispersion
United States 46.79 %
Europe 25.49 %
Asia Pacific 18.08 %
Other 9.63 %


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

RNAZ's Profile

Stock Price

RNAZ's Financials

Business Description

Fundamentals

Charts & Quotes

RNAZ's News

Suppliers

RNAZ's Competitors

Customers & Markets

Economic Indicators

RNAZ's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071